The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Cardiac recurrence time
研究概览
简要总结
Explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.
详细描述
AMO is a short acting complex I blocker that blocks mitochondrial complex I between flavoprotein and ubiquitin, and its blocking effect can be rapidly reversed. Our study is to explore the effects of amobarbital on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass, investigate the new usage of old drugs, and provide reliable clinical scientific basis for its potential value in better clinical treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation.
- •ASA II-III;
- •surgical duration is 3-6 hours;
- •Sign the informed consent form
排除标准
- •BMI less than 18 kg/m2 or greater than 30 kg/m2;
- •Individuals with a history or potential history of drug abuse or alcohol dependence;
- •Preoperative use of sedatives or analgesics;
- •Individuals with severe liver and kidney dysfunction;
- •Individuals who are allergic or potentially allergic to barbiturates;
- •Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status;
- •Participated in other clinical studies in the past 3 months;
- •The researchers believe that participants who are not suitable to participate in this study.
研究组 & 干预措施
Amo group
amobarbital 1mg/kg is given prior to cardiopulmonary bypass
干预措施: Amobarbital (Drug)
Mida group
midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
干预措施: Midazolam (Drug)
结局指标
主要结局
Cardiac recurrence time
时间窗: 1 hour after heart beat recurrence
Stop extracorporeal circulation until heart beat time
次要结局
- extubation time(1day)
- cTnI(2 days)